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Background:  The  evidence  of increased  risk  of  severe  disease  for  healthy  pregnant  women  due  to inter-
pandemic  inﬂuenza  consists  mainly  of  observational  studies  of  health  service  utilization  in  USA and
Canada.  However,  these  results  can  be  context  dependent  and estimates  in  a European  setting  are  sparse.
For policy  purposes  we  therefore  decided  to  elucidate  the  potential  value  of  vaccination  in  Sweden.
Materials  and  methods:  We  conducted  a retrospective,  register-based  study  of hospitalizations  due  to
inter-pandemic  inﬂuenza  or  respiratory  infection  attributable  to  inﬂuenza  in pregnant  women  in  Sweden.
With  aggregated  data  from  2003  to 2009  we  assessed  the  number  needed  to  vaccinate  (NNV)  to  prevent
one  such  hospitalization.
Results: We  included  on average  96,000  pregnant  women/year  and  identiﬁed  9–48  hospitaliza-
tions/season  fulﬁlling  the  case  deﬁnition.  Assuming  80%  vaccine  effectiveness  the  NNV  was  >1,900
pregnant  women.  The  estimate  is higher  than  those  found  in the USA,  Canada,  and  UK.  The  difference
may  be explained  by  differing  methods  to estimate  NNV,  but  also differences  in  propensity  to  hospitalize
and  the  basic  health  status  of  the  pregnant  women.
Conclusions: Because  of the  increased  risk  associated  with  inﬂuenza  A(H1N1)pdm09,  vaccination  is
presently  offered  to all pregnant  women  in  Sweden,  but  vaccination  against  other  inter-pandemic
inﬂuenza  types  seems  disputable.  The  study  illustrates  the  context  dependence  of  preventive  health
measures  and  points  to the  need  for national  NNV  estimates  and  international  harmonization  of study
methods  for  comparisons  between  countries.
Publis©  2014  The  Authors.  
. Introduction
Before the inﬂuenza pandemic in 2009 most European
ountries; including Sweden; recommended vaccination only of
regnant women with clinical risk-conditions; e.g. chronic heart
iseases [1]. During the pandemic; all pregnant women were con-
idered a priority group for vaccination; based on evidence of an
ncreased risk of severe disease and death associated with the
Abbreviations: NNV, number needed to vaccinate; ECDC, European Centre for
isease Prevention and Control; RIRI, respiratory infection that can possibly be
elated to inﬂuenza; NBHW, National Board of Health and Welfare; GAM, gener-
lized additive regression model; VE, vaccine effectiveness.
∗ Corresponding author at: Enheten för epidemiologi och hälsoekonomi, Folkhäl-
omyndigheten, 171 82 Solna, Sweden. Tel.: +46 10 205 23 88.
E-mail addresses: hanna.merk@folkhalsomyndigheten.se
H. Merk), gunnar.nylen@socialstyrelsen.se (G. Nylén),
haron.kuhlmann-b@folkhalsomyndigheten.se (S. Kühlmann-Berenzon),
nnika.linde@folkhalsomyndigheten.se (A. Linde).
ttp://dx.doi.org/10.1016/j.vaccine.2014.10.027
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY-NC-SA
license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
pandemic strain [2]. In the post-pandemic phase; Sweden has
decided to recommend pregnant women vaccination against
inﬂuenza A(H1N1)pdm09 with the trivalent vaccine; as long
as inﬂuenza A(H1N1)pdm09 continues to circulate and exhibit
a higher propensity to cause viral pneumonia than seasonal
inﬂuenza. However; many European countries continued to rec-
ommend vaccination to all pregnant women; not just against
A(H1N1)pdm09 but also against other strains included in the sea-
sonal vaccine [3].
There are plausible mechanisms related to mechanical and
immunological changes that may  render women more vulnera-
ble to respiratory infections during pregnancy [4,5]. The European
Centre for Disease Prevention and Control (ECDC) has concluded
that vaccination of pregnant women could reduce the number of
inﬂuenza-related hospitalizations and deaths in this group and
potentially the burden of inﬂuenza in children younger than six
months [6]. The WHO  SAGE committee has referred to “compelling
evidence of substantial risk of severe disease in this group.  . .”  [7],
and WHO  has subsequently recommended pregnant women as the
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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ighest priority group for vaccination against seasonal inﬂuenza.
owever, a recent systematic review [8] concluded that pregnancy
s a risk factor for seasonal inﬂuenza, as opposed to pandemic
nﬂuenza including A(H1N1)pdm09, is not sufﬁciently studied.
urthermore, ECDC has concluded that European studies of the dis-
ase burden of seasonal inﬂuenza in pregnant women  are needed
6]. Whereas an increased risk of inﬂuenza-associated deaths for
regnant women has been documented during pandemics [9–13],
eaths in pregnant women due to inter-pandemic inﬂuenza have
nly been described in occasional case reports [14–16], suggest-
ng that this outcome is unusual. Moreover, the evidence of an
ncreased risk of severe disease for healthy pregnant women due
o seasonal, inter-pandemic inﬂuenza mainly consists of obser-
ational studies of health service utilization in USA and Canada
17,18]. Albeit healthcare utilization often being applied as an indi-
ator of disease severity, it should be interpreted with caution since
ealthcare utilization may  be context dependent. For example,
espite similar symptoms and severity, there may  be differences in
ealthcare seeking behaviour, access to healthcare or medical rec-
mmendations. Furthermore, the relative risk does not inform on
urden of hospitalization, and a sufﬁcient absolute risk is needed to
otivate vaccination. Hospitalization rates of 15 and 25 per 10,000
regnant women or third trimester women have been found in
anada and USA, respectively [17,18], and in a study set in the UK
he rate was estimated to 13 per 10,000 pregnant women [19]. Since
hese rates may  be context dependent and estimates in a Euro-
ean setting are sparse, it was deemed that a national estimate
or Sweden was necessary for policy purposes. Therefore we con-
ucted a study of hospitalizations due to seasonal, inter-pandemic
nﬂuenza or respiratory infection attributable to inter-pandemic
nﬂuenza among pregnant women in Sweden and assessed the
umber needed to vaccinate (NNV) to prevent one such hospital-
zation.
. Methods
We  conducted a retrospective, register-based study of inter-
andemic seasons, using ICD-10 codes that indicate inﬂuenza
ospitalizations. Data for the study was collected from calendar
eek 1, 2000 to calendar week 53, 2009. For reasons explained
ater our modelling and NNV estimation subsequently required
estriction to calendar week 46, 2003–calendar week 20, 2009.
Since an inﬂuenza diagnosis may  not have been established for
ll admitted with inﬂuenza, we combined hospitalizations with
 main ICD-10 diagnosis of inﬂuenza and hospitalizations with a
ain diagnosis of a respiratory infection that can possibly be related
o inﬂuenza (RIRI) (Table 1). Regardless of the number of times the
iagnosed individuals were admitted and discharged during a cal-
ndar week, a maximum of one hospitalization episode per week
nd person was included.
There is no register on all pregnancies in Sweden, but there
s a Medical Birth Register. Therefore only pregnant women  who
ad given birth in Sweden were eligible for our study. The register
ncludes women who delivered a living child, or a deceased child
fter 27 weeks (before June 2008) or after 21 weeks (thereafter).
The national registration numbers of the women who  had given
irth during the study period were collected from the Swedish
edical Birth Register and linked to the National Patient Regis-
er. Both registers are kept by the National Board of Health and
elfare (NBHW). Identiﬁed cases with a main diagnosis belong-
ng to either inﬂuenza or RIRI were categorized as such. Nearly all
regnant women in Sweden regularly attend prenatal care [20].
onetheless 3–8% of the women lacked a registered date of their
ast period, or an ultrasound estimated date of beginning of their
regnancy, and were excluded from the study. Based on the date of (2014) 7135–7140
the beginning of the pregnancy trimesters were approximated (1st:
≤84 days, 2nd: 85–182 days, 3rd: ≥183 days). Finally, the number
of pregnant women  was aggregated by calendar week, year and
trimester. The data was extracted and aggregated by the NBHW
and thereafter delivered to the investigators. Since the study was
carried out with aggregated data it did not require a review by an
Ethics Review Board.
To estimate the number of hospitalizations with RIRI that could
be attributed to inﬂuenza but for which the main diagnosis was
not inﬂuenza, we ﬁtted a generalized additive (GAM) quasi-Poisson
regression model with identity link [21] to the RIRI hospitalizations.
The model included: calendar week, which modelled the baseline
with a cyclic penalized cubic regression spline function; and the
weekly number of laboratory inﬂuenza reports with one parameter
for each season, which modelled hospitalizations above the base-
line that could be attributed to inﬂuenza. By using identity link
we could assume that these hospitalizations were proportional to
the laboratory inﬂuenza cases. We  also calculated Wald conﬁdence
intervals for the proportions. During the included time period,
94–95% of all pregnant women  were 20–39 years old [22]. There-
fore the included laboratory data on the weekly national number
of conﬁrmed laboratory results of inﬂuenza during the surveillance
seasons, i.e. calendar weeks 40–20, for seasons 2003/04–2008/09,
were collected for the 20–39 years age group. This laboratory
surveillance data was  collected from the Swedish Institute for
Communicable Disease Control and linked to the weekly patient
data. Data by age group was  only available from calendar week
46, 2003 and onwards, and data beyond calendar week 20, 2009
were excluded to avoid the inclusion of the pandemic inﬂuenza
A(H1N1)pdm09.
The estimated proportions were multiplied with the weekly
number of laboratory inﬂuenza cases, resulting in the weekly num-
ber of RIRI hospitalizations attributed to inﬂuenza among pregnant
women. The weekly numbers were then aggregated per season.
For each season, 2003/04–2008/09 we also extracted the total
number of main diagnoses of inﬂuenza in the register data during
the extended season, deﬁned as the time between calendar week 27
one year to calendar week 26 the following year. In 2009 the last
included week was week 20. There were no inﬂuenza diagnoses
outside the surveillance season.
We  then added the inﬂuenza diagnoses in each extended sea-
son to the estimated RIRI hospitalizations attributed to inﬂuenza,
calculated from the model, and thereby obtained an estimate of the
total number of inﬂuenza hospitalizations of pregnant women per
season.
As part of our main analysis we  also calculated the NNV per
season [23]
NNVi =
1
VEi
( casesi
nk
) , (1)
where VE = vaccine effectiveness against inﬂuenza, cases = total
number of inﬂuenza hospitalizations per season, n = number of
unvaccinated pregnant women, i = season and k = year the season
turned into. We  assumed that all pregnant women were unvacci-
nated, and thus n was  the number of pregnant women between
2003 and 2009. The VE was allowed to vary in order to carry out
a sensitivity analysis: 40–80%. This wide range of VE was chosen
since estimations of the VE and its conﬁdence intervals have varied
widely between studies [24,25] and the match to the circulating
subtype of inﬂuenza may  vary. We also calculated the mean NNV
using the average n and the average cases.To create the possible worst and best case scenarios of NNV, we
ﬁrst calculated the 95% conﬁdence intervals of number of hospi-
talizations attributable to inﬂuenza for each season. For the worst
possible scenario, the most severe season, we substituted the cases
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Table  1
The included ICD-10 codes with their respective diagnoses and how they were grouped. Hospitalizations with a main diagnosis of a respiratory infection that can possibly be
related to inﬂuenza and that are common inﬂuenza complications, grouped as RIRI diagnoses, and hospitalizations with a main diagnosis of inﬂuenza grouped as inﬂuenza
diagnoses.
ICD-10 RIRI diagnosis ICD-10 Inﬂuenza diagnosis
J00 Acute nasopharyngitis [common cold] J09 Inﬂuenza due to certain identiﬁed inﬂuenza virus
J01.0  Acute maxillary sinusitis J10.0 Inﬂuenza with pneumonia, other inﬂuenza virus
identiﬁed
J01.1  Acute frontal sinusitis J10.1 Inﬂuenza with other respiratory manifestations, other
inﬂuenza virus identiﬁed
J01.2  Acute ethmoidal sinusitis Inﬂuenzal:
J01.3 Acute sphenoidal sinusitis Acute upper respiratory infection
J01.4  Acute pansinusitis Laryngitis
J01.8 Other acute sinusitis Pharyngitis
J01.9 Acute sinusitis, unspeciﬁed Pleural effusion
J02.0  Streptococcal pharyngitis J10.8 Inﬂuenza with other manifestations, other inﬂuenza
virus identiﬁed
J02.8  Acute pharyngitis due to other speciﬁed organisms Encephalopathy due to inﬂuenza
J02.9  Acute pharyngitis, unspeciﬁed Inﬂuenzal:
J04.0 Acute laryngitis Gastroenteritis
J04.1 Acute tracheitis Myocarditis (acute)
J04.2  Acute laryngotracheitis J11.0 Inﬂuenza with pneumonia, virus not identiﬁed
J05.0  Acute obstructive laryngitis [croup] J11.1 Inﬂuenza with other respiratory manifestations, virus
not identiﬁed
J06.0 Acute laryngopharyngitis Inﬂuenza NOS
J06.8  Other acute upper respiratory infections of multiple sites Inﬂuenzal:
J06.9 Acute upper respiratory infection, unspeciﬁed Acute upper respiratory infection
J12.9  Viral pneumonia, unspeciﬁed Laryngitis
J13  Pneumonia due to Streptococcus pneumoniae Pharyngitis
J14  Pneumonia due to Haemophilus inﬂuenzae Pleural effusion
J15.2  Pneumonia due to staphylococcus J11.8 Inﬂuenza with other manifestations, virus not
identiﬁed
J15.3  Pneumonia due to streptococcus, group B Encephalopathy due to inﬂuenza
J15.4  Pneumonia due to other streptococci Inﬂuenzal:
J15.8 Other bacterial pneumonia Gastroenteritis
J15.9 Bacterial pneumonia, unspeciﬁed Myocarditis (acute)
J18.0  Bronchopneumonia, unspeciﬁed
J18.1 Lobar pneumonia, unspeciﬁed
J18.8 Other pneumonia, organism unspeciﬁed
J18.9 Pneumonia, unspeciﬁed
J20.1 Acute bronchitis due to Haemophilus inﬂuenzae
J20.2 Acute bronchitis due to streptococcus
J20.8 Acute bronchitis due to other speciﬁed organisms
J20.9 Acute bronchitis, unspeciﬁed
J21.8 Acute bronchiolitis due to other speciﬁed organisms
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wJ21.9 Acute bronchiolitis, unspeciﬁed
J22 Unspeciﬁed acute lower respiratory infection
arameter for the maximum of all conﬁdence interval limits; and
or the best possible scenario, the mildest season, the minimum of
ll limits. Each scenario included the previously described range of
E.
As subanalyses we calculated the total number of inﬂuenza hos-
italizations by the ﬁrst, second and third trimesters.
For our analysis we used STATA IC 10 and R 2.15.0 with package
gcv 1.7–22.
. Results
During 2000–2009 the yearly incidence of pregnant women who
elivered a child ranged from 87,866–109,594. Ofﬁcial statistics for
000–2009 show that 94–95% of all pregnant women in Sweden
ere 20–39 years, 87–92% were non-smokers and non-snuff con-
umers in early pregnancy, and the average BMI  at prenatal care
nrolment was 24.3–24.6 [22]. After exclusion of those who lacked
he date of the beginning of their pregnancy, the included num-
er of pregnant women ranged from 80,842–100,777 per year.
n the inﬂuenza diagnosis group (n = 121) the three most com-
on  main diagnoses that had required hospitalization among the
ncluded women were: inﬂuenza with other respiratory mani-
estations, other inﬂuenza virus identiﬁed, J10.1 (36%); inﬂuenza
ith other respiratory manifestations, virus not identiﬁed, J11.1(34%); and inﬂuenza due to certain identiﬁed inﬂuenza virus, J09
(15%). In the RIRI diagnosis group (n = 745) the most common main
diagnoses were: pneumonia, unspeciﬁed, J18.9 (19%); acute upper
respiratory infection, unspeciﬁed, J06.9 (19%); and bacterial pneu-
monia, unspeciﬁed, J15.9 (11%).
According to the GAM model, during three out of seven included
seasons, a signiﬁcant proportion of the RIRI hospitalizations were
attributable to inﬂuenza (Figure 1). The total number of inﬂuenza
hospitalizations of pregnant women, including both inﬂuenza
and the RIRI attributable to inﬂuenza, was  9–48 per season
(Table 2).
Given the assumptions made, we estimated the NNV to prevent
one hospitalization of a pregnant woman due to inﬂuenza or RIRI
attributable to inﬂuenza for a VE range from 40% to 80% (Table 3).
The average annual number of pregnant women during the time
period possible to include in our modelling was 96,116; for the
mean NNV it was  approximated to 96,000.
The scenarios with the highest (worst scenario) and lowest
number of inﬂuenza hospitalizations (best scenario), as estimated
with the conﬁdence intervals, resulted for all tested scenarios in
>1,900 pregnant women having to be vaccinated to prevent one
hospitalization due to inﬂuenza in the target population (Table 4).
However, were the inﬂuenza season mild, and the VE 40% then the
NNV would be 40,069 (Table 4).
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Table 2
The number of registered inﬂuenza hospitalizations (A), the estimated number of RIRI hospitalizations that had not received a main diagnosis of inﬂuenza but were attributable
to  inﬂuenza (B), the total number of estimated and registered inﬂuenza hospitalizations (A + B), the number of pregnant women the year the season turned into (C), the
combined rate of estimated and registered inﬂuenza hospitalizations per 100,000 pregnant women, per season 2003/2004–2008/2009. RIRI = hospitalization with main
diagnosis of a respiratory infection that can possibly be related to inﬂuenza.
Season No. of registered
inﬂuenza
hospitalizations (A)
Estimated no. of RIRI
hospitalizations
attributable to inﬂuenza (B)
Total no. estimated and
registered inﬂuenza
hospitalizations (A + B)
No. of pregnant women
the year the season
turned into (C)
The combined rate of estimated and
registered inﬂuenza hospitalizations per
100,000 pregnant women (A + B)/(C)
2003/2004 14 11 25 95,629 26.1
2004/2005 7 9 16 93,514 17.1
2005/2006 6 3 9 96,166 9.4
2006/2007 7 29 36 95,453 37.7
2007/2008 10 26 36 99,236 36.3
2008/2009 10 38 48 100,777 47.6
Average 9 20 29 96,000a 30.2
a The average includes year 2003 with 92,033 pregnant women.
Table 3
Number needed to vaccinate to prevent one hospitalization due to inﬂuenza or another respiratory infection attributable to inﬂuenza by vaccine effectiveness and estimated
total  number of inﬂuenza hospitalizations for pregnant women  by season and on average.
Number of hospitalizations
due to inﬂuenza
Season Vaccine effectiveness (%)
40 50 60 70 80
Minimum 9 2005/2006 26,713 21,370 17,809 15,264 13,356
16  2004/2005 14,612 11,689 9,741 8,349 7,306
25  2003/2004 9,563 7,650 6,375 5,465 4,781
Average 29  – 8,276 6,621 5,517 4,729 4,138
36  2006/2007 6,629 5,303 4,419 3,788 3,314
36  2007/2008 6,891 
Maximum 48 2008/2009 5,249 
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Fig. 1. (a) Fitted number of hospitalizations with respiratory infections that can pos-
sibly be related to inﬂuenza (RIRI), per week in Sweden 2003–2009. (b) Proportion
of inﬂuenza cases hospitalized as RIRI per season according to the GAM model, with
95% conﬁdence intervals. These graphs do not include speciﬁc inﬂuenza diagnoses.
For  details see text.
Table 4
The best and worst case scenario for number needed to vaccinate to prevent one hospital
Number of hospitalizations
due to inﬂuenza
Season Vaccine effectiveness (
40 
Worst 65 2008/2009 3, 876 
Best  6 2005/2006 40,  069 5,513 4,594 3,938 3,446
4,199 3,499 2,999 2,624
The subanalysis for women  in their ﬁrst trimester yielded an
average number of 6 hospitalizations due to inﬂuenza or respiratory
infection attributable to inﬂuenza, range between 1–10 per season.
For women  in their second and third trimester the range was 6–26
and 1–14, with averages of 14 and 11 hospitalizations, respectively.
4. Discussion
In this national register-based study of infectious disease
hospitalizations due to inter-pandemic inﬂuenza, covering six
heterogeneous inter-pandemic seasons in pregnant women, we
estimated the average number of hospitalizations per season to 29,
with a range from 9 to 48 per season. Moreover, we estimated that
>1,900 pregnant women would have to be vaccinated to prevent
one hospitalization with a main diagnosis of respiratory infec-
tion attributable to inﬂuenza. The strengths of our study are the
inclusion of six recent heterogeneous inﬂuenza seasons, and the
use of national register data. Furthermore the outcome included
the estimated number of hospitalization due to inﬂuenza based
on a statistical model of the respiratory infections that have been
assessed as reasonable to attribute to inﬂuenza, instead of includ-
ing all respiratory infections indiscriminately. This also increased
our ability to allow for variations in diagnoses patterns over time.
Indeed, the RIRI diagnoses attributable to inﬂuenza increased for
the latter seasons unlike the speciﬁc inﬂuenza diagnoses.
ization due to inﬂuenza by vaccine effectiveness.
%)
50 60 70 80
3,101 2,584 2,215 1,938
32,055 26,713 22,897 20,035
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A weakness of the study is that we included pregnant women
ith underlying conditions. Therefore our NNV is an underesti-
ate of the NNV among healthy pregnant women. However, from
 policy perspective, we aimed for a minimum NNV estimate in
 Swedish context. Even so, in Sweden our NNV estimates were
onsidered high.
Other weaknesses relate to underlying assumptions behind our
NV results: that all pregnant women were unvaccinated and
t risk of contracting inﬂuenza, and that any effect of vaccina-
ion of other population groups can be disregarded. All of these
ssumptions can be debated on different grounds and there is
nfortunately limited information to assess their importance. For
xample, the assumption that all the pregnant women are unvacci-
ated is not correct because in Sweden pregnant women  belonging
o risk-groups were recommended vaccination. Thus, our NNV
ould be overestimated. However, the vaccine uptake is unknown
ut estimated by the profession to be very low (<5%).
Finally, the estimates do not take into account that the same
ndividual may  be hospitalized repeatedly during one season, nor
oes the model include other infectious agents that may  cause
ome of the hospitalizations, nor the time-point for vaccination
n relation to epidemic inﬂuenza activity. This may  lead to an
nderestimate of the NNV. On the other hand, the following may
ave led to an overestimation of the NNV: hospitalizations with
ther diagnoses, e.g. exacerbations of pulmonary or cardiac condi-
ions, were not included; neither were secondary diagnoses, which
ould have included inﬂuenza although the main diagnosis did not;
or the effect the vaccine could have on infants, including small-
or-gestational-age [26] and symptomatic inﬂuenza infection [27].
owever, with regard to infant hospitalization, few children <6
onths were hospitalized with inﬂuenza as main diagnosis. In
003–2009, 3–15 cases/season were identiﬁed, although some
ases may  be undiagnosed [28].
Our estimate of the absolute risk of hospitalization in an aver-
ge season with 80% VE resulted in an NNV of 4,138. However,
ew studies have evaluated the effectiveness of seasonal inﬂuenza
accination during pregnancy, especially there is a paucity of
ntervention-studies with veriﬁed inﬂuenza as outcome [29]. If VE
nstead is 60% then the NNV would exceed 5,500, but in a more
evere season NNV could be 3,499. Since severity predictions may
e difﬁcult, a policy decision would have to allow for regularly
ccurring mild seasons such as in 2005/2006. In addition, neu-
aminidase inhibitors were not recommended to pregnant women
n Sweden during the study period, and the NNV might have been
ven higher had they been used at the time [30,31].
Our subanalysis by trimester differed from others who found an
ncreasing hospitalization rate by trimester [17]. This might be due
o differences in context, less observations in our study, or because
e included fewer ICD codes which may  have more impact on the
hird trimester when doctors may  be more prone to admit pregnant
atients.
Our mean NNV is higher than the NNV assessments from USA
nd Canada of 500 [17] and 750–900 [18], respectively. In Europe
he evaluations of NNV have tended to be higher than the USA
stimate. However, the European estimates are diverging. The
etherlands has assessed that at least 1,500 pregnant women
ithout risk-conditions need to be vaccinated to avoid one hos-
italization [32], a result more similar to our estimate of >1,900.
n the other hand, based on results from a UK study [19], we cal-
ulated an NNV of 962 assuming 80% VE and a hospitalization rate
f approximately 13 hospitalizations per 10,000 women. Sweden
nd the UK had similar life expectancy among women  [33], total
ertility rate [34] and mean age of childbearing [34], in 2005–2010,
ut there are differences with regard to the study designs and the
opulations which might help explain the disparity in the results.
irst, unlike our study, the UK study included all ICD codes between (2014) 7135–7140 7139
J0–J4, but on the other hand excluded women  belonging to a risk
group. The exclusion of risk groups probably had a larger impact on
the hospitalization rate than the inclusion of more diagnoses. Had
the UK study included the risk groups as we did, that would have
increased the hospitalization rate and further decreased the NNV,
therefore not explaining the differences observed. Second, although
Sweden had a higher overall hospital discharge rate, 163 vs. 138
per 1,000 persons [35], the hospital discharge rate for respiratory
disease was  higher for the UK, 11.8 vs. 10.2 per 1,000 inhabitants
[36]. These differences in discharge rates could support the theory
that the NNV results differ because the UK pregnant women  suf-
fer from more severe respiratory disease or that these diagnoses
more readily result in hospital admission in the UK than in Sweden.
These data point to the importance for future studies to identify the
reasons behind different national NNV estimates. It also illustrates
the need to determine absolute hospitalization rates in the actual
target population, since these are context dependent and can be
cumbersome to recalibrate to other settings.
5. Conclusions
Seasonal inﬂuenza vaccine is regarded as safe for pregnant
women [37]. Despite this we  believe that the present contradict-
ing assessments of the evidence of excess risk of inter-pandemic
inﬂuenza infections for healthy pregnant women [7,8] and our
comparatively high NNV ﬁndings [17–19] indicate that the ratio-
nale for general vaccination of pregnant women  is weak, if the
A(H1N1)pdm09 largely ceases to cause viral pneumonia. Focus-
ing on increasing the vaccination in pregnant women belonging to
medical risk-groups may  be a more cost-effective and so far scien-
tiﬁcally more well-founded approach [8]. However, ultimately, the
decision to vaccinate or not will also have to be guided by context
dependent factors e.g. incidence of other diseases and the feasibility
of different prevention methods.
Finally, we infer that much could be gained by conducting a
European-wide retrospective, register-based study of the hospital
admissions of pregnant women, with special focus on inﬂuenza.
Harmonized study methods for all countries would enable national
estimates of NNV and comparisons of the results between countries
that would not be hampered by different modelling strategies but
rather reﬂect the circumstances in each country.
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